RESULTS	A comparable proportion of VF ( res ) patients in each group developed nonnucleoside reverse transcriptase inhibitor resistance-associated mutations ( RAMs ) [ rilpivirine : 6/16 ( 38 % ) vs. efavirenz : 5/12 ( 42 % ) ] .\